Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP9 | P14780 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26115730 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MMP2MMP9MAPTNPSR1 | |
| SCHEMBL30630098 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MMP2MMP9MAPTNPSR1 | |
| SCHEMBL26114053 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MMP2MMP9MAPTNPSR1 | |
| SCHEMBL30630067 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MMP2MMP9MAPTNPSR1 | |
| SCHEMBL26115550 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MMP2MMP9MAPTNPSR1 | |
| SCHEMBL30242673 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLS | |
| SCHEMBL28989527 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLS | |
| SCHEMBL14560517 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLS | |
| SCHEMBL10215924 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLS | |
| SCHEMBL22559317 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MAPTNPSR1CASP3GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325378-A | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | 柯巴斯医药有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | ALDH1A1 2140/4885MMP2 4517/4885MMP9 4264/4885 |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | ALDH1A1 2463/4885MMP2 4140/4885MMP9 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.